Thermo Fisher Scientific experienced strong upward momentum driven by notable institutional backing and favorable strategic positioning. A key catalyst behind the positive price action was the company’s inclusion in JPMorgan’s top growth stock selections for the month. Institutional endorsements of this nature often trigger refreshed buy-side interest, encouraging portfolio managers to rotate capital into high-quality healthcare and life sciences names. Concurrently, recent regulatory filings highlighted continued institutional accumulation, reinforcing confidence in the company’s long-term fundamental trajectory.

Market enthusiasm is also building around the broader recovery in life sciences research and biopharmaceutical spending….